BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 25776904)

  • 1. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
    Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
    Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
    Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
    Hong IK; Kim SY; Chung JH; Lee SJ; Oh SJ; Lee SJ; Oh J; Ryu JS; Kim TW; Kim DY; Moon DH
    Anticancer Res; 2014 Feb; 34(2):759-66. PubMed ID: 24511010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
    Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
    Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; Atadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO
    Cancer Res; 2006 Aug; 66(15):7621-9. PubMed ID: 16885362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
    Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
    Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
    Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
    Temmink OH; Prins HJ; van Gelderop E; Peters GJ
    Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
    Sakamoto K; Yokogawa T; Ueno H; Oguchi K; Kazuno H; Ishida K; Tanaka N; Osada A; Yamada Y; Okabe H; Matsuo K
    Int J Oncol; 2015; 46(6):2327-34. PubMed ID: 25901475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
    Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
    J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
    Schelhaas S; Held A; Wachsmuth L; Hermann S; Honess DJ; Heinzmann K; Smith DM; Griffiths JR; Faber C; Jacobs AH
    Cancer Res; 2016 Dec; 76(24):7096-7105. PubMed ID: 27784748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
    Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
    Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.